TherapeuticsMD, Inc.
NASDAQ Global SelectTotal Valuation
TherapeuticsMD, Inc. carries a market capitalization of 25.58M, placing it among publicly traded companies globally. Its enterprise value stands at 25.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 25.58M |
| Enterprise Value | 25.58M |
Share Statistics
TherapeuticsMD, Inc. currently has 11.57M shares outstanding.
| Shares Outstanding | 11.57M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
TherapeuticsMD, Inc. trades at a trailing price-to-earnings ratio of 128.98.
| PE Ratio | 128.98 |
| PS Ratio | 10.65 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | 11.08 |
| P/OCF Ratio | 11.03 |
Enterprise Valuation
| EV / Sales | 10.65 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 11.02 |
Financial Position
TherapeuticsMD, Inc. maintains a current ratio of 9.06, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 67.93, indicating elevated leverage, while an interest coverage ratio of -651.00 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.06 |
| Quick Ratio | 6.98 |
| Debt / Equity | 67.93 |
| Debt / EBITDA | N/A |
| Interest Coverage | -651.00 |
Financial Efficiency
| Return on Equity (ROE) | -2.73 |
| Return on Assets (ROA) | -1.93 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 1.46 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 32,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
TherapeuticsMD, Inc.'s stock has gained approximately 104.62963% over the past 52 weeks. The 50-day moving average sits at 2.09, while the 200-day moving average is 2.07.
| Beta (5Y) | N/A |
| 52-Week Price Change | 104.62963% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 2.07 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, TherapeuticsMD, Inc. generated 2.40M in revenue and converted that into -372,000.00 in net income, yielding earnings per share of -0.04. EBITDA reached -1.95M, while operating income came in at -3.05M.
| Revenue | 2.40M |
| Gross Profit | N/A |
| Operating Income | -3.05M |
| Pretax Income | -427,000.00 |
| Net Income | -372,000.00 |
| EBITDA | -1.95M |
| EBIT | -3.05M |
| Earnings Per Share (EPS) | -0.04 |
Cash Flow
TherapeuticsMD, Inc. produced 2.32M in operating cash flow over the past twelve months.
| Operating Cash Flow | 2.32M |
| Capital Expenditures | N/A |
| Free Cash Flow | 2.32M |
| FCF Per Share | 0.20 |
Margins
TherapeuticsMD, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -126.99 and net profit margin of -15.49 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -126.99 |
| Pretax Margin | -17.78 |
| Profit Margin | -15.49 |
| EBITDA Margin | -81.34 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | 9.03 |
Stock Splits
TherapeuticsMD, Inc.'s most recent stock split took place on May 9, 2022 with a 50:1 split ratio.
| Last Split Date | 5/9/2022 |
| Split Ratio | 50:1 |
Scores
TherapeuticsMD, Inc. posts an Altman Z-Score of -113.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -113.70 |